Further evaluations, including quantitative assessment of contrast ratios in patient-derived tumors versus normal lung tissues, will be essential to conclusively determine the appropriateness of Nectin-4-targeted imaging in clinical NSCLC diagnosis and monitoring. This evidence concerns the gene NECTIN4 and non-small cell lung carcinoma.